IPO Year: 2023
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/25/2024 | $89.00 | Buy | Canaccord Genuity |
5/10/2024 | $80.00 | Buy | BofA Securities |
12/20/2023 | $43.00 | Buy | BTIG Research |
8/8/2023 | Outperform | TD Cowen | |
8/8/2023 | $40.00 | Outperform | Wedbush |
8/8/2023 | $29.00 | Buy | Guggenheim |
8/8/2023 | $34.00 | Buy | Stifel |
8/8/2023 | $29.00 | Buy | Jefferies |
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
S-3ASR - Apogee Therapeutics, Inc. (0001974640) (Filer)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development,
SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna's knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors' selection decision. "We are thrilled to welcome Mark as chair of our board and to
Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months Single dose showed deep and sustained inhibition of key atopic dermatitis biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available with inhibition still ongoing at time of data cut) APG777 was well tolerated with a favorable safety profile consistent with the anti-IL-13 class Company plans to initiate a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis in 1H 2024 with induction r
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Apogee's website at https://investors.apogeeth
Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00
BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00
BTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00
TD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform
Wedbush initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $40.00
Guggenheim initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00
Stifel initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $34.00
Jefferies initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing 16-week topline data from APG777 Phase 2 Part A trial in AD accelerated to mid-2025 based on strong enrollment Preclinical and coformulation proof-of-concept achieved for APG777 + APG990 combination Phase 1b head-to-head trial against DUPIXENT expected to initiate in 2025 with data in 2H 2026 Preclinical proof-of-concept achieved for APG7
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025 APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025; potential to offer best-in-class combination efficacy across multiple respiratory indications Plans advancing for combination studies, starting with the first clinical trial of the APG777 and APG990 combination for the treatment of AD in 2025 $754 million cash,
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences. Guggenheim Inaugural Healthcare Innovation Conference Date: Tuesday, November 12, 2024Time: 3:00 p.m. ET Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time:
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved treatments for moderate-to-severe AD Key biomarker data from single doses of APG777 show near complete inhibition of pSTAT6 and sustained TARC inhibition up to 9 months Proof-of-concept data from the ongoing APG777 Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis are expected in 2H 2025 APG777 has the potential to demonstrate improved clinical responses from greater exposures in induction and maintenance dosing of every 3- or 6-months SAN FRANCISCO and WALT
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T. A live and archived webcast of the fireside chat and presentation will
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results. Methode Electronics reported a fourth-quarter fiscal 2024 net sales decline of 7.9% year-on-year to $277.30 million, beating the analyst consensus estimate of $264.04 million. Adjusted EPS loss of 23 cents missed the analyst consensus loss estimate of 20 cents, according to data from Benzinga Pro. Methode Electronics shares surged 29.4% to $12.22 on Thursday. Here are some other big stocks recording gains in today’s session.
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansionSAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammat
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications, today reported pipeline highlights and first quarter financial results. "I am proud of the continued momentum our team has achieved this quarter, executing against our goals and successfully bringing our programs forward ahead of schedule," said Michael Henderson, MD, Chief Executive Officer of Apogee. "We continue to maintain that pace of progress with the selection of our development candidate for APG990 and now plan to ini
B of A Securities analyst Geoff Meacham initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $80.
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Molina Healthcare, Inc. (NYSE:MOH) On March 6, Barclays analyst Andrew Mok initiated coverage o
The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.